人工瓣膜置换术后再次外科干预的原因与预后分析
该回顾性病例系列研究纳入144例人工瓣膜置换术后再次心脏瓣膜手术患者,分析再次干预原因及近中期疗效。生物瓣组再干预主因为结构性瓣膜衰败(71.8%),机械瓣组主因为血管翳或血栓形成(69.7%)及瓣周瘘(22.7%)。术后30天病死率6.3%,1年生存率90.8%,术前肾功能不全、重度三尖瓣关闭不全、人工瓣膜心内膜炎、心源性休克和急诊手术与术后死亡风险增加相关。
要点
- 生物瓣置换后再干预主因为结构性瓣膜衰败(71.8%),机械瓣后主因为血管翳或血栓形成(69.7%)及瓣周瘘(22.7%)。
- 再次瓣膜手术后30天病死率6.3%,1年生存率90.8%(95%CI:86.2%~95.7%)。
- 术前肾小球滤过率、重度三尖瓣关闭不全、人工瓣膜心内膜炎、心源性休克和急诊手术是术后死亡的独立影响因素。
核心结论
- 生物瓣置换术后再次外科干预的主要原因是结构性瓣膜衰败,机械瓣术后主要是血管翳或血栓形成和瓣周瘘。
- 术前肾功能不全、重度三尖瓣关闭不全、人工瓣膜心内膜炎、心源性休克和急诊手术可能增加再次手术后死亡风险。
研究设计与样本
- 回顾性病例系列研究,连续纳入2020年7月至2025年7月在南京市第一医院心胸血管外科行二次或多次心脏瓣膜手术的144例患者。
- 排除前次手术为瓣膜成形或经导管瓣膜植入术,以及再次手术未处理前次植入人工瓣的患者。
- 男性80例,女性64例,年龄63(14)岁(范围:29~78岁);二次手术140例(97.2%),三次手术4例(2.8%)。
- 前次手术行二尖瓣、主动脉瓣和三尖瓣置换分别占71.5%、56.3%和2.1%,28.5%同时接受二尖瓣和主动脉瓣置换。
- 按前次瓣膜类型分为生物瓣组78例和机械瓣组66例。
主要发现
- 再次手术与前次手术中位时间间隔11(9)年(范围:3个月至32年)。
- 生物瓣组再干预原因:结构性瓣膜衰败71.8%(56/78),人工瓣膜心内膜炎21.8%(17/78)。
- 机械瓣组再干预原因:血管翳或血栓形成69.7%(46/66),瓣周瘘22.7%(15/66)。
- 术后30天病死率6.3%(9/144),低心排出量综合征10.4%(15/144),永久起搏器植入8.3%(12/144),机械通气延长22.2%(32/144)。
- 随访12(12)个月(范围:0~42个月),5例死亡(4例心源性,1例非心源性);1年生存率90.8%(95%CI:86.2%~95.7%)。
关键数值与推荐
- 多因素Cox回归显示肾小球滤过率(HR=0.97,95%CI:0.95~1.00,P=0.019)、重度三尖瓣关闭不全(HR=6.41,95%CI:1.31~31.17,P=0.022)、人工瓣膜心内膜炎(HR=3.67,95%CI:1.06~12.73,P=0.041)、术前心源性休克(HR=7.70,95%CI:3.14~27.73,P=0.002)、急诊或抢救性手术(HR=7.39,95%CI:1.82~30.09,P=0.005)是术后死亡的独立影响因素。
临床怎么用
- 对生物瓣置换术后患者应关注结构性瓣膜衰败,对机械瓣术后患者应关注血管翳或血栓形成及瓣周瘘。
- 再次瓣膜手术前应评估肾功能、三尖瓣关闭不全程度、人工瓣膜心内膜炎、心源性休克及手术紧迫性,以识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the causes of surgical reintervention after prosthetic valve replacement and to evaluate the safety and effectiveness of valve reoperation. Methods: This retrospective case series study consecutively included 144 patients who underwent repeat cardiac valve surgery at the Department of Cardiothoracic Surgery, Nanjing First Hospital between July 2020 and July 2025. Patients were excluded if their initial procedure involved valve repair or transcatheter valve implantation, or if the previously implanted prosthetic valve was not treated during the reoperation. There were 80 males and 64 females. The age (M(IQR)) was 63(14) years (range:29 to 78 years).One hundred and forty patients (97.2%,140/144) underwent a second cardiac surgery, while 4 patients(2.8%,4/144) underwent a third operation.In the previous surgery, mitral, aortic and tricuspid valve replacement had been performed on 71.5%(103/144), 56.3%(81/144) and 2.1%(3/144) patients respectively, and 28.5%(41/144) patients had undergone concomitant mitral and aortic valve replacement. A total of 78 patients had previously received bioprosthetic valves (bioprosthetic group), and 66 patients had previously received mechanical valves (mechanical group). The causes of reintervention, all-cause mortality after reoperation, and the incidence of major perioperative complications were analyzed. Independent sample t-test, Mann-Whitney U test, Chi-square test or Fisher's exact test was used in between-group analysis. Kaplan-Meier method was performed on survival analysis. Univariate and multivariate Cox regression analyses were used to identify the risk factors for all-cause mortality after surgery in patients. Results: The interval from the previous surgerymedian was 11(9) years (range:3 months to 32 years). In the bioprosthetic group, the main causes of reintervention were structural valve deterioration (71.8%, 56/78) and prosthetic valve endocarditis (21.8%, 17/78). In the mechanical group, the leading causes were pannus or valve thrombosis (69.7%, 46/66) and paravalvular leak (22.7%, 15/66). Reoperations involved the mitral valve in 88 cases, the aortic valve in 62 cases, and the tricuspid valve in 3 cases. All patients underwent reoperation via median sternotomy, and 72.2% (104/144) received peripheral cannulation. The 30-day mortality rate was 6.3% (9/144). The incidences of low cardiac output syndrome, permanent pacemaker implantation, and prolonged mechanical ventilation were 10.4% (15/144), 8.3% (12/144), and 22.2% (32/144), respectively. The follow-up time was 12(12) months(range:0 to 42 months), 5 patients died during the follow-up period, among whom 4 died of cardiac causes and 1 died of non-cardiac causes. The Kaplan-Meier survival analysis showed that the 1-year survival rate of the patients after surgery was 90.8% (95%CI: 86.2% to 95.7%). The univariate and multivariate Cox regression analysis results indicated that glomerular filtration rate (HR=0.97, 95%CI: 0.95 to 1.00, P=0.019), severe tricuspid regurgitation (HR=6.41, 95%CI: 1.31 to 31.17, P=0.022), prosthetic valve endocarditis (HR=3.67, 95%CI: 1.06 to 12.73, P=0.041), preoperative cardiogenic shock (HR=7.70, 95%CI: 3.14 to 27.73, P=0.002), and emergency or salvage surgery (HR=7.39, 95%CI: 1.82 to 30.09, P=0.005) were independent risk factors for postoperative mortality in patients undergoing revalvularization. Conclusions: Structural valve deterioration is the primary cause of surgical reintervention after bioprosthetic valve replacement, whereas pannus or valve thrombosis and paravalvular leak are the main reasons after mechanical valve replacement. Preoperative renal insufficiency, severe tricuspid regurgitation, prosthetic valve endocarditis, cardiogenic shock, and emergency surgery are significantly associated with increased postoperative mortality after valve reoperation. 目的: 探讨人工瓣置换术后再次外科干预的原因和手术近中期疗效。 方法: 本研究为回顾性病例系列研究。回顾性分析2020年7月至2025年7月在南京市第一医院心胸血管外科行二次或多次心脏瓣膜手术的144例患者资料,其中不包括前次手术为瓣膜成形或经导管瓣膜植入术,以及再次手术未处理前次植入人工瓣的患者。男性80例,女性64例,年龄[M(IQR)]63(14)岁(范围:29~78岁)。本次手术为二次手术的患者140例(97.2%,140/144),三次手术的患者4例(2.8%,4/144)。前次手术行二尖瓣、主动脉瓣和三尖瓣置换的患者分别占71.5%(103/144)、56.3%(81/144)和2.1%(3/144),其中28.5%(41/144)的患者前次手术同时接受了二尖瓣和主动脉瓣置换。根据前次手术使用瓣膜类型,分为生物瓣置换术后78例(生物瓣组),机械瓣置换术后66例(机械瓣组)。分析患者再次干预的原因,再次手术后的全因病死率以及围术期主要并发症发生率等。组间比较采用独立样本t检验、Mann-Whitney U检验、χ2检验或Fisher确切概率法,采用Kaplan-Meier法进行生存分析。使用单因素和多因素Cox回归分析患者术后全因死亡的危险因素。 结果: 再次手术与前次手术中位时间间隔11(9)年(范围:3个月至32年)。生物瓣组再干预的主要原因包括:结构性瓣膜衰败(71.8%,56/78),人工瓣膜心内膜炎(21.8%,17/78)。机械瓣组再干预的主要原因包括:血管翳或血栓形成(69.7%,46/66)、瓣周瘘(22.7%,15/66)。144例患者在本次手术中行再次二尖瓣置换88例次,再次主动脉瓣置换62例次,再次三尖瓣置换3例次。所有患者再次手术均采用胸骨正中切口,72.2%(104/144)行外周插管。术后30 d病死率为6.3%(9/144),低心排出量综合征发生率为10.4%(15/144),永久起搏器植入率为8.3%(12/144),机械通气延长率为22.2%(32/144)。患者术后随访12(12)个月(范围:0~42个月),5例患者随访中死亡,其中4例为心源性死亡,1例为非心源性死亡。Kaplan-Meier生存分析结果显示,患者术后1年生存率为90.8%(95%CI:86.2%~95.7%)。单因素和多因素Cox回归分析结果显示,肾小球滤过率(HR=0.97,95%CI:0.95~1.00,P=0.019)、重度三尖瓣关闭不全(HR=6.41,95%CI:1.31~31.17,P=0.022)、人工瓣膜心内膜炎(HR=3.67,95%CI:1.06~12.73,P=0.041)、术前心源性休克(HR=7.70,95%CI:3.14~27.73,P=0.002)、急诊或抢救性手术(HR=7.39,95%CI:1.82~30.09,P=0.005)是再次瓣膜手术患者的术后死亡的独立影响因素。 结论: 生物瓣置换术后再次外科干预的主要原因是结构性瓣膜衰败,而机械瓣术后再次干预的原因主要是血管翳或血栓形成和瓣周瘘。术前肾功能不全、重度三尖瓣关闭不全、人工瓣膜心内膜炎、心源性休克和急诊手术可能增加再次手术后死亡风险。.
引用
- Wang WW, Xiang F, Wang LM, et al. [Reasons for surgical reintervention and its prognosis after prosthesis valve replacement]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41881795. doi:10.3760/cma.j.cn112139-20251209-00583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。